Tech Company Financing Transactions
Attralus Funding Round
On 9/9/2021, Attralus raised $116 million in Series B funding from Logos Capital, Janus Henderson Investors and Redmile Group.
Transaction Overview
Company Name
Announced On
9/9/2021
Transaction Type
Venture Equity
Amount
$116,000,000
Round
Series B
Investors
Logos Capital (Lead Investor) (Graham Walmsley)
venBio (Richard Gaster)
Proceeds Purpose
Proceeds from the financing will be used to prepare the advancement of Attralus' PAR therapeutics into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Timney
Chief Financial Officer
Benson Fong
Chief Medical Officer
Gregory Bell
Chief Operating Officer
Spencer Guthrie
Chief Scientific Officer
Jonathan Wall
VP - Bus. Development
Glen Firestone
VP - Bus. Development
Krishna Gorti
VP - Human Resources
Christine Huh
Browse more venture capital transactions:
Prev: 9/9/2021: Orbit Fab venture capital transaction
Next: 9/9/2021: Replicate Bioscience venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs